Compare AbbVie Inc (ABBV) vs iShares 7-10 Year Treasury Bond ETF (IEF) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs iShares 7-10 Year Treasury Bond ETF — how do they compare? AbbVie Inc trades at $253.76 (market cap $449.91B), while iShares 7-10 Year Treasury Bond ETF trades at $93.45. The key difference: AbbVie Inc pays a 2.72% dividend while iShares 7-10 Year Treasury Bond ETF pays none, and AbbVie Inc is trading nearer its 52-week high, iShares 7-10 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | IEF | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | — |
52-Week High | $261.07 | $97.99 |
52-Week Low | $184.85 | $93.11 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
IEF, a US stock, trades at $93.7, down 0.45% over 24 hours, with a bearish technical signal driven by moving averages. Recent corporate actions include dividend payments scheduled for mid-2026. The stock lacks key valuation and profitability ratios in the provided data, limiting fundamental assessment. News highlights bond market dynamics and Federal Reserve policy uncertainty influencing sentiment.
The outlook for IEF is cautious due to bearish technical indicators and macroeconomic headwinds like potential rate hikes. Investment opportunities may arise from dividend distributions, but risks include market volatility and Fed policy shifts. Investors should weigh technical weakness against income potential in a fluctuating interest rate environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About iShares 7-10 Year Treasury Bond ETF
The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity of greater than or equal to seven years and less than ten years. The fund will invest at least 80% of its assets in the component securities of the underlying index, and the fund will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index.
Read more on IEF →
